Insight Molecular Diagnostics (IMDX) EBIAT: 2020-2025
Historic EBIAT for Insight Molecular Diagnostics (IMDX) over the last 6 years, with Sep 2025 value amounting to -$10.9 million.
- Insight Molecular Diagnostics' EBIAT rose 19.56% to -$10.9 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$60.8 million, marking a year-over-year decrease of 40.87%. This contributed to the annual value of -$60.7 million for FY2024, which is 118.36% down from last year.
- Insight Molecular Diagnostics' EBIAT amounted to -$10.9 million in Q3 2025, which was down 11.41% from -$9.7 million recorded in Q2 2025.
- Insight Molecular Diagnostics' 5-year EBIAT high stood at $6.0 million for Q1 2023, and its period low was -$45.0 million during Q4 2022.
- Moreover, its 3-year median value for EBIAT was -$9.1 million (2024), whereas its average is -$10.3 million.
- Per our database at Business Quant, Insight Molecular Diagnostics' EBIAT crashed by 468.79% in 2021 and then spiked by 157.90% in 2023.
- Quarterly analysis of 5 years shows Insight Molecular Diagnostics' EBIAT stood at -$35.9 million in 2021, then decreased by 25.34% to -$45.0 million in 2022, then skyrocketed by 64.44% to -$16.0 million in 2023, then plummeted by 109.55% to -$33.5 million in 2024, then climbed by 19.56% to -$10.9 million in 2025.
- Its EBIAT was -$10.9 million in Q3 2025, compared to -$9.7 million in Q2 2025 and -$6.7 million in Q1 2025.